CR9100A - Metodos y sistemas para el pronostico y tratamiento de tumores solidos - Google Patents

Metodos y sistemas para el pronostico y tratamiento de tumores solidos

Info

Publication number
CR9100A
CR9100A CR9100A CR9100A CR9100A CR 9100 A CR9100 A CR 9100A CR 9100 A CR9100 A CR 9100A CR 9100 A CR9100 A CR 9100A CR 9100 A CR9100 A CR 9100A
Authority
CR
Costa Rica
Prior art keywords
systems
treatment
solid tumors
present
forecast
Prior art date
Application number
CR9100A
Other languages
English (en)
Inventor
E Burczynski Michael
J Dorner Andrew
C Twine Natalie
L Trepicchio William
K Slonim Donna
Strahs Andrew
Immermann Frederick
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9100A publication Critical patent/CR9100A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion proporciona metodos, sistemas y equipo para el pronostico y tratamiento de carcinoma de celulas renales (RCC) u otros tumores solidos. Los genes de pronostico de resultados clinicos de un tumor solido se pueden identificar de acuerdo con la presente invencion. Los perfiles de expresion de estos genes en celulas monunucleares de sangre periferica (PBMC) de pacientes quienes presentan el tumor solido se relacionan con el resultado clinico de estos pacientes.
CR9100A 2004-11-22 2007-05-04 Metodos y sistemas para el pronostico y tratamiento de tumores solidos CR9100A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62968104P 2004-11-22 2004-11-22

Publications (1)

Publication Number Publication Date
CR9100A true CR9100A (es) 2007-08-28

Family

ID=36463527

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9100A CR9100A (es) 2004-11-22 2007-05-04 Metodos y sistemas para el pronostico y tratamiento de tumores solidos

Country Status (15)

Country Link
US (1) US20060134671A1 (es)
EP (1) EP1815024A2 (es)
JP (1) JP2008520251A (es)
KR (1) KR20070084488A (es)
CN (1) CN101068936A (es)
AU (1) AU2005312081A1 (es)
BR (1) BRPI0518036A (es)
CA (1) CA2588253A1 (es)
CR (1) CR9100A (es)
IL (1) IL182813A0 (es)
MX (1) MX2007005764A (es)
NI (1) NI200700126A (es)
NO (1) NO20072296L (es)
RU (1) RU2007117507A (es)
WO (1) WO2006060265A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004097052A2 (en) * 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
GB0717101D0 (en) * 2007-09-03 2007-10-10 Cambridge Entpr Ltd Tumour marker
EP2265328B1 (en) * 2008-03-20 2018-05-09 EBS Technologies GmbH An apparatus for automatic treatment adjustment after nervous system dysfunction
WO2011150976A1 (en) 2010-06-04 2011-12-08 bioMérieux Method and kit for the prognosis of colorectal cancer
WO2011153684A1 (en) * 2010-06-08 2011-12-15 Biomerieux Method and kit for the prognosis of colorectal cancer
CN106148508B (zh) * 2010-06-08 2019-12-03 生物梅里埃公司 用于结肠直肠癌预后的方法和试剂盒
US9315869B2 (en) 2010-12-13 2016-04-19 Samsung Life Public Welfare Foundation Marker for predicting gastric cancer prognosis and method for predicting gastric cancer prognosis using the same
WO2012129758A1 (en) 2011-03-25 2012-10-04 Biomerieux Method and kit for determining in vitro probability for individual to suffer from colorectal cancer
WO2015187129A1 (en) * 2014-06-03 2015-12-10 Hewlett-Packard Development Company, L.P. Document classification based on multiple meta-algorithmic patterns
US11193172B2 (en) * 2015-01-09 2021-12-07 Tokyo University Of Science Foundation Method for predicting prognosis of patient with cancer or inflammatory disease
CN108624650B (zh) * 2018-05-14 2022-04-29 乐普（北京）医疗器械股份有限公司 判断实体瘤是否适合免疫治疗的方法和检测试剂盒
CN109355385B (zh) * 2018-11-16 2022-02-08 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Linc00266-1 rna作为实体瘤标志物的应用
US11721441B2 (en) * 2019-01-15 2023-08-08 Merative Us L.P. Determining drug effectiveness ranking for a patient using machine learning
CN110634571A (zh) * 2019-09-20 2019-12-31 四川省人民医院 肝移植术后预后预测系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3944996B2 (ja) * 1998-03-05 2007-07-18 株式会社日立製作所 Ｄｎａプローブアレー
US6647341B1 (en) * 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
WO2001053312A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
US20030165854A1 (en) * 2000-12-05 2003-09-04 Cunningham Mary Jane Marker genes responding to treatment with toxins
WO2004097052A2 (en) * 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors

Also Published As

Publication number Publication date
IL182813A0 (en) 2007-08-19
AU2005312081A1 (en) 2006-06-08
JP2008520251A (ja) 2008-06-19
EP1815024A2 (en) 2007-08-08
CN101068936A (zh) 2007-11-07
BRPI0518036A (pt) 2008-10-28
CA2588253A1 (en) 2006-06-08
NO20072296L (no) 2007-08-20
WO2006060265A2 (en) 2006-06-08
US20060134671A1 (en) 2006-06-22
MX2007005764A (es) 2007-07-20
KR20070084488A (ko) 2007-08-24
NI200700126A (es) 2008-05-09
WO2006060265A3 (en) 2007-01-04
RU2007117507A (ru) 2008-12-27

Similar Documents

Publication Publication Date Title
CR9100A (es) Metodos y sistemas para el pronostico y tratamiento de tumores solidos
Jolly et al. Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
Xie et al. TERT promoter mutations and gene amplification: promoting TERT expression in Merkel cell carcinoma
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
Shinmei et al. MicroRNA‐155 is a predictive marker for survival in patients with clear cell renal cell carcinoma
WO2005044990A3 (en) Use of differentially expressed nucleic acid sequences as biomarkers for cancer
EP4435112A3 (en) Compositions and methods for screening solid tumors
Rice et al. Lymph node metastases in patients with urothelial carcinoma variants: influence of the specific variant on nodal histology
McLean et al. Concurrent primary and metastatic cutaneous head and neck squamous cell carcinoma: analysis of prognostic factors
WO2011112903A3 (en) Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
CR9298A (es) Marcadores farmacogenomicos para el pronostico de tumores solidos
MXPA05004971A (es) Pronostico para malignidad hematologica.
MXPA06014175A (es) Diagnostico o pronostico del curso del cancer de mama.
Vogelsang et al. Germline determinants of clinical outcome of cutaneous melanoma
Nylander et al. Changes in miRNA expression in sera and correlation to duration of disease in patients with multifocal mucosal lichen planus
CY1117701T1 (el) Δραστηριοτητα του τέμσιρολιμου κατα των ογκων στον καρκινο θηλοειδων νεφρικων κυτταρων
Yao et al. A promising natural killer cell-based model and a nomogram for the prognostic prediction of clear-cell renal cell carcinoma
Farhadieh et al. Radiotherapy in larynx squamous cell carcinoma is not associated with an increased diagnosis of second primary tumours
Lianidou et al. Advances in circulating tumor cells (ACTC): from basic research to clinical practice
EP2588631A4 (en) PROTEIN KINASE CK2 GEN MUTATIONS, REINFORCEMENTS AND POLYMORPHISMS IN HUMAN CANCER AND METHOD OF USE
He et al. Construction of IL-1 signalling pathway correlation model in lung adenocarcinoma and association with immune microenvironment prognosis and immunotherapy: multi-data validation
Wang et al. Association between GLS gene polymorphisms and the susceptibility to lung cancer in the Chinese Han Population
Lalisang Validation of simplified predictive score for postoperative mortality after pancreaticoduodenectomy

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)